Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Gastric Cancer Clinical Trial

Official title:

A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05415098
• Other study ID #: APG5918XG101
• Status: Recruiting
• Phase: Phase 1
• Start date: September 30, 2022
• Est. completion date: September 30, 2025

Study information

• Verified date: November 2022
• Source: Ascentage Pharma Group Inc.
• Contact: Wendy Chu
• Phone: 240-278-6373
• Email: wendy.chu[@]ascentage.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally. Patients will be treated in 28-day cycles.

Description:

The dose escalation part is to establish the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) when APG-5918 is given orally once daily in subjects with histologically- and/or cytologically-confirmed advanced solid tumors or non-Hodgkin's lymphoma (NHL) that have progressed or are intolerant after treatment with approved therapies or for which there are no standard therapies available. The starting dose of APG-5918 is 50 mg; the doses can be modified depending on toxicity and pharmacokinetic (PK) results based on discussions with the Investigators and Sponsor. If no dose-limiting toxicities (DLTs) or less than two drug related Grade 2 toxicities are observed by the end of Cycle 1, the dose of APG-5918 will be increased in subsequent cohorts. The dose expansion part will be initiated once the MTD or RP2D is established. Approximately 9-12 subjects will be enrolled into two cohorts treating with the appropriate two dose levels at (MTD-1 and MTD) or below MTD (MTD-2 and MTD-1), depending on the comprehensive analysis of the PK, pharmacodynamic (PD), safety and efficacy data of APG-5918. Patients will be randomized 1:1 to each dose cohort.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: September 30, 2025
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 in dose escalation or 0 to 2 in dose expansion
• Has a life expectancy of >3 months
• Has a malignancy: with histologically or cytologically confirmed locally advanced or metastatic solid tumors or relapsed or refractory Non-Hodgkin's Lymphoma (NHL) who have disease progression after treatment with available therapies that are known to confer clinical benefit.

1. has measurable disease based on RECIST 1.1 for advanced solid tumors including but not limited to nasopharyngeal carcinoma, castration-resistant prostate cancer, gastric cancer, ovarian clear cell carcinoma, mesothelioma, and sarcoma

2. has measurable disease based on Non-Hodgkin's Lymphoma Cheson response criteria for NHL

• For subjects with B cell lymphoma: has documented EZH2 mutation status or be willing to perform EZH2 mutation status testing
• For subjects with sarcoma: patients with epithelioid sarcoma or sarcoma with confirmed evidence of aberrant SMARCB1 status is preferred
• For subjects with prostate cancer: patients must have evidence of castration resistance (as evidenced by confirmed elevated prostate-specific antigen (PSA) (per Prostate Cancer Working Group [PCWG3] criteria) and serum testosterone of castrate levels (i.e. = 50 ng/dL))
• Adequate hematologic function defined as:

1. ANC =1.0 x 10^9/L independent of growth factor support within 7 days of the first dose with study drug

2. Hemoglobin =9 g/dL without transfusion or growth factor support within 7 days of the first dose of study drug

3. Platelet count = 75 x 10^9/L without transfusion support within 7 days of the first dose of study drug

• Adequate hepatic and renal function defined as:

1. AST and ALT = 3 x upper limit of normal (ULN) (= 5 x ULN if liver metastases)

2. Calculated creatinine clearance = 50 mL/min using the Cockcroft-Gault formula

3. Total Bilirubin =1.5 x ULN (Except if considered secondary to Gilbert's syndrome and primarily indirect bilirubinemia)

• PT and aPTT =2 x ULN
• Troponin = 2 x ULN
• QTcF interval =470ms for all genders (mean (triplicate) n =3), measured between 2-5 minutes apart
• Stable brain metastases with clinically controlled neurologic symptoms
• Willingness to use contraception by either true abstinence or the use of a method that is deemed effective by the investigator by both males and female patients of childbearing potential and their partners throughout the treatment period and for at least three months following the last dose of study drug. Note: Female participants of

non-child-bearing potential are defined as:

1. surgically sterile,

2. postmenopausal for 12 months, or

3. receiving a stable dose of oral, implanted, transdermal or injectable contraceptive for at least 3 months with the last dose of injectable contraceptive within 2 months (Nonsurgical menopause history must be confirmed by follicle-stimulating hormone and luteinizing hormone levels as defined by established laboratory ranges)

• Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures)
• Willingness and ability to comply with study procedures and follow-up examination

Exclusion Criteria:

• Receiving concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, with the exception of hormones for hypothyroidism or estrogen replacement therapy (ERT), anti-estrogen analogs, agonists required to suppress serum testosterone levels); or any investigational therapy within 14 days or 5 times of half-life of the molecule prior to the first dose of study drug
• Steroid therapy for anti-neoplastic intent within 7 days prior to the first dose of the study drug
• Continuance of toxicities due to prior radiotherapy, targeted therapy, immunotherapy or chemotherapeutic agents that do not recover to < Grade 2, except alopecia or leukodermia
• Has gastrointestinal conditions that could affect the absorption of APG-5918 in the opinion of the Investigator
• Use of therapeutic doses of anti-coagulants is excluded, along with antiplatelet agents; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are permitted
• Received a biologic (G-CSF, GM-CSF, or erythropoietin) within 7 days prior to the first dose of the study drug
• Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.
• Severe cardiac conditions defined as:

1. New York Heart Association (NYHA) class III or IV cardiac disease, including preexisting uncontrolled clinically significant arrhythmia, congestive heart failure, or cardiomyopathy

2. Unstable angina, myocardial infarction, or a coronary revascularization procedure within = 3 months prior to initiation of study treatment

3. Echocardiography showing left ventricular ejection fraction (LVEF) < 50%

4. poorly controlled hypertension, or history of poor compliance with antihypertensive drug regimens

• Symptomatic brain metastases per clinical evaluation due to tumor involvement of the central nervous system (CNS). Patients with CNS tumors that have been treated are asymptomatic and who have discontinued steroids (for the treatment of CNS tumors) for = 28 days may be enrolled.
• Active symptomatic fungal, bacterial, and/or viral infection. Patients with well controlled human immunodeficiency virus (HIV), hepatitis B or C can be enrolled.
• Prior treatment with embryonic ectoderm development (EED) inhibitors
• Concurrent treatment with QT interval-prolonging drugs
• Medical history of Torsades de Pointes
• Patients with known or suspected allergy or hypersensitivity to drugs/compounds similar in composition to APG-5918 or other EED inhibitors
• Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study
• Other malignant diseases than the ones being treated in this study with the exception of: cured malignancy without recurrence within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of any type
• Non-Hodgkin lymphoma patients who have received prior allogeneic stem cell transplant
• Severe and/or uncontrolled medical conditions that in the investigator's opinion could affect the safety of individual or impair the assessment of study result
• Long-term steroid therapy, except for the following: 10 mg prednisone (or equivalent) daily or lower doses of steroids for control of nausea, vomiting, active autoimmune disease and seasonal allergies or prevention of adrenocortical insufficiency Note: topical steroids or inhaled steroids are allowed
• Pregnant (confirmed by human chorionic gonadotropin (HCG) testing) or lactating women

Related Conditions & MeSH terms

• B Cell Lymphoma
• Carcinoma
• Castrate Resistant Prostate Cancer
• Epithelioid Sarcoma
• Gastric Cancer
• Lymphoma
• Mesothelioma
• Nasopharyngeal Carcinoma
• Non Hodgkin Lymphoma
• Ovarian Clear Cell Carcinoma
• Sarcoma

Intervention

Drug:
• APG-5918
The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles. The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study.

Locations

Country	Name	City	State
United States	Highlands Oncology	Springdale	Arkansas

Sponsors (1)

Lead Sponsor	Collaborator
Ascentage Pharma Group Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting Toxicity (DLT)	DLTs will be assessed via CTCAE version 5.0	28 days